Beckman Coulter’s PK7400 Automated Microplate System Receives 510(k) FDA Clearance

Beckman Coulter today announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its PK7400 Automated Microplate System and the system’s reagents have completed FDA approval.

Designed for use in blood donor and plasma centers, as well as large reference laboratories, the PK7400 Automated Microplate System offers the industry’s highest throughput for a single analyzer in its class and is now available in countries across Europe, Canada and the United States.

According to the AABB (formerly the American Association of Blood Banks), an estimated 33,000 units of blood are needed each day to meet patient need. However, the organization also stated, more than 4,000 blood donation events have been cancelled due to the COVID-19 pandemic.

“Blood donation is critically important under normal circumstances, as one donation can save up to three lives, but even more so now,” said Shamiram R. Feinglass, M.D., MPH, chief medical officer, Beckman Coulter. “During this challenging time, those that are feeling well and healthy should continue to make and keep donation appointments to help ensure life-saving blood is available for patients that need it most.”

“Along with the need for physical donors, blood donation and plasma centers require tools that enable them to reliably test and process the samples that are coming in, so they can quickly make them available for patients,” said Kathleen Orland, vice president and general manager of Beckman Coulter’s Chemistry and Immunoassay business. “Our PK7400 is designed to optimize workflow, minimize hands-on time and increase productivity, allowing users to focus their time on protecting the health and safety of donors, patients and blood center staff.”

The PK7400 Automated Microplate System:

  • Offers the industry’s highest throughput for a single analyzer in its class, processing up to 300 samples per hour with a maximum of 12 tests per sample
  • Includes proprietary liquid and ready-to-use reagents
  • Provides the end user the ability to test multiple assays in a single batch without decreasing the throughput
    • The assay menu includes ABO blood grouping, Rh typing, weak D testing, Rh-Kell phenotyping, as well as syphilis and CMV qualitative screening

“The PK7400 is a user-friendly analyzer with the capacity to test a large throughput with rapid, accurate results,” said Christie Garza, laboratory specialist at Gulf Coast Regional Blood Center. “The software is easy to navigate, and results can be interpreted quickly and easily.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”